Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-negative breast cancer market, with coverage of multiple settings; neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.
Overall five year survival in breast cancer is relatively high, at around 90%, but this is subjective to the subtype and stage of the disease. Importantly this report segments HER2 negative breast cancer into its two major subtypes; hormone receptor positive (HR+) and triple negative breast cancer (TNBC).
There are several reasons for this decline, the most important of which is the fact that fewer drugs will be entering fewer settings in the Japanese market than in the US and 5EU, in particular, NeuVax in the highly lucrative adjuvant setting, and several premium-priced PARP inhibitors in the TNBC setting. Japan will also see the highest number of patent expiries (six) of any of the forecast countries, which will result in significant downsizing and curtailment of growth compared with the rest of the world. Japan also has a steadily declining population (AGR = -0.03%), meaning that the total potential patient pool that could be eligible for any given drug is reduced. Furthermore, the higher drug prices observed in the US and 5EU compared with the more modest prices observed in Japan, will contribute to the decline in the Japanese market.
- Overview of HER2-Negative Breast Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product HER2-Negative Breast Cancercription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan HER2-Negative Breast Cancer market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HER2-Negative Breast Cancer.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 9
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Basic Breast Anatomy 15
3.2 Disease Classification/Staging Systems 16
3.3 Symptoms 18
3.4 Prognosis 18
3.5 Quality of Life 19
4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 22
4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 24
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 28
4.2 Japan 29
4.2.1 Diagnosis 29
4.2.2 Clinical Practice 30
5 Competitive Assessment 33
5.1 Overview 33
5.2 Product Profiles (Branded Therapies) 34
5.2.1 Abraxane (nab-paclitaxel) 34
5.2.2 Afinitor (everolimus) 39
5.2.3 Avastin (bevacizumab) 43
5.2.4 Doxil/Caelyx (pegylated liposomal doxorubicin) 48
5.2.5 Halaven (eribulin mesylate) 53
5.2.6 Ixempra (ixabepilone) 56
5.2.7 Xeloda (capecitabine) 59
5.3 Product Profiles (Hormonal Agents) 62
5.3.1 Tamoxifen 62
5.3.2 Faslodex (fulvestrant) 62
5.3.3 Aromatase Inhibitors 63
6 Unmet Need and Opportunity 67
6.1 Overview 67
6.1.1 Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries 69
6.1.2 Specific treatment options for TNBC patients 71
6.1.3 Prevention of brain metastasis 72
6.1.4 Neoadjuvant therapy that can downstage tumors 74
6.1.5 For HR+patients, reduced resistance to hormonal agents 75
6.1.6 Improved convenience of administration of hormonal agents 77
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.